Your browser doesn't support javascript.
loading
Synergistic neuromodulation therapy for persistent spinal pain: a proof-of-concept trial on the use of spinal cord and dorsal root ganglion stimulation.
Fiedler, Augusto Müller; Piedade, Guilherme Santos; Assumpção de Monaco, Bernardo; Taylor, Ruby Rose; Williams, Michelle Dawn; Danny, John L; Minor, Adrienne; Cordeiro, Joacir Graciolli.
Afiliação
  • Fiedler AM; Department of Neurological Surgery, University of Miami, 1475 NW 12th Ave, Miami, FL, 33136, USA. mullerfiedler.augusto@gmail.com.
  • Piedade GS; Department of Neurological Surgery, University of Miami, 1475 NW 12th Ave, Miami, FL, 33136, USA.
  • Assumpção de Monaco B; Department of Neurological Surgery, University of Miami, 1475 NW 12th Ave, Miami, FL, 33136, USA.
  • Taylor RR; Division of Neurosurgery, Clinics Hospital, University of São Paulo, São Paulo, Brazil.
  • Williams MD; Department of Neurological Surgery, University of Miami, 1475 NW 12th Ave, Miami, FL, 33136, USA.
  • Danny JL; Medical Scientist Training Program, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Minor A; Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Cordeiro JG; Department of Neurological Surgery, University of Miami, 1475 NW 12th Ave, Miami, FL, 33136, USA.
Acta Neurol Belg ; 2024 May 18.
Article em En | MEDLINE | ID: mdl-38761329
ABSTRACT

PURPOSE:

Persistent Spinal Pain Syndrome type 2 (PSPS-T2) poses a significant clinical challenge, demanding innovative therapeutic interventions. The integration of Spinal Cord Stimulation (SCS) and Dorsal Root Ganglion Stimulation (DRG-S) is emerging as a potent synergistic strategy for comprehensive pain management. This single patient-blind proof of concept (POC) trial explores the efficacy and synergistic potential of combined SCS and DRG-S in a patient with refractory PSPS-T2.

METHODS:

A 45-year-old male with intractable PSPS-T2 underwent a unique, methodically structured study, involving three treatment phases Phase A with SCS alone, Phase B with DRG-S alone, and Phase C The patient, blinded to the treatment modalities, provided pain assessments using the Visual Analogue Scale (VAS) and Douleur Neuropathique 4 Questions (DN4) conducted by clinical investigators at each phase. Baseline pain scores were ten and nine, respectively.

RESULTS:

Distinct responses were noted across the phases. Phase A demonstrated moderate pain relief, while Phase B offered further pain intensity reduction. However, Phase C, combining both strategies, yielded the most significant improvement, remarkably enhancing the patient's quality of life and functional capacity.

CONCLUSION:

This POC trial underscores the synergistic potential of SCS and DRG-S in managing complex cases of PSPS-T2, suggesting a paradigm shift towards integrated neuromodulation strategies for enhanced pain control. The development of dual intent implantable pulse generators (IPGs) capable of offering combination therapy simultaneously might be effective for pain management in select cases. The significant pain reduction and functional improvement observed advocate for further research in dual neuromodulation therapies. TRIAL REGISTRATION NUMBER IRB 20190536.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article